Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis.Can J Cardiol. 2020; 36: 322-334
- Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.N Engl J Med. 2018; 379: 1007-1016
- Canadian drug expert reimbursement recommendations: tafamidis meglumine.Canadian Agency for Drugs and Technology in Health, Ottawa, Ontario2020: 1-8
- The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.Circulation. 2007; 116: 2216-2233
- Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis.Am J Cardiol. 2014; 113: 1723-1727
See page 1645 for disclosure information.